Key Points
-
Natural killer (NK) cells respond to cytokines, stress signals, microbial products and molecules that are expressed on infected or transformed cells. They are therefore important in the defence against infection and cancer.
-
Although it is generally accepted that NK-cell generation takes place in the bone marrow of adults, the features that make the bone marrow well suited for NK-cell development remain ill-defined.
-
Haematopoietic stem cells (HSCs) successively restrict their potential to generate different blood cell lineages. Recently, commited NK-cell progenitors (NKPs) have been identified.
-
A two-step stromal cell-free culture system has defined the minimal cytokine requirements for NK-cell generation in vitro. In a first phase, HSCs become committed to the NK-cell lineage; and in the second phase, they become killer cells under the influence of interleukin-15.
-
The final maturation of NK cells, including acquisition of expression of MHC-specific inhibitory and activating receptors, depends on contact with stromal cells.
-
A better understanding of NK-cell development could improve the use of these effector cells in diverse pathological states.
Abstract
We know how B and T cells develop, what they 'see' and the receptors they 'see with'. By contrast, and despite an unprecedented increase in the number of receptors and ligands known to regulate the activity of natural killer (NK) cells, we still have many questions regarding how these cells develop. Nevertheless, we are beginning to understand the transcriptional programmes of NK-cell maturation and the role of the effector functions of NK cells in the regulation of immune responses. An improved knowledge of NK-cell development in mice and humans might be useful to harness the power of these natural killers in the clinic to fight autoimmune diseases, infection and cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Matsunaga, T. & Rahman, A. What brought the adaptive immune system to vertebrates? The jaw hypothesis and the seahorse. Immunol. Rev. 166, 177–186 (1998).
Medzhitov, R. & Janeway, C. Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89–97 (2000).
Colucci, F., Di Santo, J. P. & Leibson, P. J. Natural killer cell activation in mice and men: different triggers for similar weapons? Nature Immunol. 3, 807–813 (2002). A recent update on receptors, ligands and signalling molecules that regulate natural killer (NK)-cell activation.
Godin, I. & Cumano, A. The hare and the tortoise: an embryonic haematopoietic race. Nature Rev. Immunol. 2, 593–604 (2002). An excellent review of haematopoiesis with special emphasis on the comparison between formation of blood cells in the embryo and in the adult.
Seaman, W. E., Gindhart, T. D., Greenspan, J. S., Blackman, M. A. & Talal, N. Natural killer cells, bone, and the bone marrow: studies in estrogen-treated mice and in congenitally osteopetrotic (mi/mi) mice. J. Immunol. 122, 2541–2547 (1979).
Kumar, V., Ben-Ezra, J., Bennett, M. & Sonnenfeld, G. Natural killer cells in mice treated with 89strontium: normal target-binding cell numbers but inability to kill even after interferon administration. J. Immunol. 123, 1832–1838 (1979).
Herberman, R. B., Nunn, M. E., Holden, H. T. & Lavrin, D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16, 230–239 (1975).
Sirianni, M. C., Businco, L., Seminara, R. & Aiuti, F. Severe combined immunodeficiencies, primary T-cell defects and DiGeorge's syndrome in humans: characterization by monoclonal antibodies and natural killer cell activity. Clin. Immunol. Immunopathol. 28, 361–370 (1983).
Sihvola, M. & Hurme, M. The development of NK cell activity in thymectomized bone marrow chimeras. Immunology 53, 17–22 (1984).
Ramos, S. B., Garcia, A. B., Viana, S. R., Voltarelli, J. C. & Falcao, R. P. Phenotypic and functional evaluation of natural killer cells in thymectomized children. Clin. Immunol. Immunopathol. 81, 277–281 (1996).
Schwarz, R. E. & Hiserodt, J. C. Effects of splenectomy on the development of tumor-specific immunity. J. Surg. Res. 48, 448–453 (1990).
Passlick, B. et al. Posttraumatic splenectomy does not influence human peripheral blood mononuclear cell subsets. J. Clin. Lab. Immunol. 34, 157–161 (1991).
Phillips, J. H. et al. Ontogeny of human natural killer cells: fetal NK cells mediate cytolytic functions and express cytoplasmic CD3ε, δ proteins. J. Exp. Med. 175, 1055–1063 (1992).
Jaleco, A. C. et al. Fetal liver contains committed NK progentiors, but is not a site for the development of CD34+ cells into T cells. J. Immunol. 159, 694–702 (1997).
Mingari, M. C. et al. In vitro proliferation and cloning of CD3−CD16+ cells from human thymus precursors. J. Exp. Med. 174, 21–30 (1991).
Rodewald, H. -R. et al. A population of early fetal thymocytes expressing FcγR II/III contains precursors of T lymphocytes and natural killer cells. Cell 69, 139–146 (1992).
Ikawa, T., Kawamoto, H., Fujimoto, S. & Katsura, Y. Commitment of common T/natural killer (NK) progenitors to unipotent T and NK progenitors in the murine fetal thymus revealed by a single progenitor assay. J. Exp. Med. 190, 1617–1626 (1999).
Rosmaraki, E. E. et al. Identification of committed NK cell progenitors in adult murine bone marrow. Eur. J. Immunol. 31, 1900–1909 (2001). The first description of a committed NK-cell precursor in the bone marrow of adult mice. Its human counterpart has not been identified.
Spits, H. et al. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol. Rev. 165, 75–86 (1998).
Bennett, I. M. et al. Definition of a natural killer NKR-P1A+/CD56−/CD16− functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12. J. Exp. Med. 184, 1845–1856 (1996).
Miller, J. S., Alley, K. A. & McGlave, P. Differentiation of NK cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood 83, 2594–2601 (1994).
Shibuya, A., Nagayoshi, K., Nakamura, K. & Nakauchi, H. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood 85, 3538–3546 (1995).
Mrozek, E., Anderson, P. & Caligiuri, M. A. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87, 2632–2640 (1996).
Williams, N. S. et al. Generation of lytic natural killer 1.1+, Ly-49− cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J. Exp. Med. 186, 1609–1614 (1997). Reference 23 and 24 describe the minimal cytokine requirements (stromal-cell free) for generating NK cells in vitro . This process is remarkably similar in humans and mice.
Dokun, A. O. et al. Specific and nonspecific NK cell activation during virus infection. Nature Immunol. 2, 951–956 (2001).
Salazar-Mather, T. P., Orange, J. S. & Biron, C. A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J. Exp. Med. 187, 1–14 (1998).
Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661–668 (2000).
Akashi, K., Traver, D., Miyamoto, T. & Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197 (2000).
Kondo, M., Weissman, I. L. & Akashi, K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661–672 (1997).
Igarashi, H., Gregory, S. C., Yokota, T., Sakaguchi, N. & Kincade, P. W. Transcription from the RAG1 locus marks the earliest lymphocyte progenitors in bone marrow. Immunity 17, 117–130 (2002).
Sivori, S. et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc. Natl Acad. Sci. USA 99, 4526–4531 (2002).
Yu, H. et al. Flt3 ligand promotes the generation of a distinct CD34+ human natural killer cell progenitor that responds to interleukin-15. Blood 92, 3647–3657 (1998).
Lyman, S. D. & Jacobsen, S. E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91, 1101–1134 (1998).
Colucci, F. & Di Santo, J. P. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood 95, 984–991 (2000).
Waskow, C., Paul, S., Haller, C., Gassmann, M. & Rodewald, H. Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity 17, 277–288 (2002).
Sitnicka, E. et al. Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. Immunity 17, 463–472 (2002).
Mackarehtschian, K. et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3, 147–161 (1995).
McKenna, H. J. et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95, 3489–3497 (2000).
Spritz, R. A. Molecular basis of human piebaldism. J. Invest. Dermatol. 103, S137–S140 (1994).
Billia, F., Barbara, M., McEwen, J., Trevisan, M. & Iscove, N. N. Resolution of pluripotential intermediates in murine hematopoietic differentiation by global complementary DNA amplification from single cells: confirmation of assignments by expression profiling of cytokine receptor transcripts. Blood 97, 2257–2268 (2001).
Warren, L. A. & Rothenberg, E. V. Regulatory coding of lymphoid lineage choice by hematopoietic transcription factors. Curr. Opin. Immunol. 15, 166–175 (2003).
Wang, J. H. et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537–549 (1996).
Tucker, S. N., Jessup, H. K., Fujii, H. & Wilson, C. B. Enforced expression of the Ikaros isoform IK5 decreases the numbers of extrathymic intraepithelial lymphocytes and natural killer 1.1+ T cells. Blood 99, 513–519 (2002).
Nichogiannopoulou, A., Trevisan, M., Neben, S., Friedrich, C. & Georgopoulos, K. Defects in hemopoietic stem cell activity in Ikaros mutant mice. J. Exp. Med. 190, 1201–1214 (1999).
Bories, J. C. et al. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature 377, 635–638 (1995).
Barton, K. et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 9, 555–563 (1998).
Scott, E. W., Simon, M. C., Anastasi, J. & Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265, 1573–1577 (1994).
Colucci, F. et al. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 97, 2625–2632 (2001).
DeKoter, R. P., Lee, H. J. & Singh, H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity 16, 297–309 (2002).
Radtke, F. et al. Notch1 deficiency dissociates the intrathymic development of dendritic cells and T cells. J. Exp. Med. 191, 1085–1094 (2000).
Schaniel, C., Bruno, L., Melchers, F. & Rolink, A. G. Multiple hematopoietic cell lineages develop in vivo from transplanted Pax5-deficient pre-B I-cell clones. Blood 99, 472–478 (2002).
Engel, I. & Murre, C. The function of E- and Id proteins in lymphocyte development. Nature Rev. Immunol. 1, 193–199 (2001).
Heemskerk, M. H. et al. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 186, 1597–1602 (1997).
Spits, H., Couwenberg, F., Bakker, A. Q., Weijer, K. & Uittenbogaart, C. H. Id2 and Id3 inhibit development of CD34+ stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-DC2. J. Exp. Med. 192, 1775–1784 (2000).
Yokota, Y. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397, 702–726 (1999). The first example of a transcription factor that selectively affects NK-cell development.
Ikawa, T., Fujimoto, S., Kawamoto, H., Katsura, Y. & Yokota, Y. Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc. Natl Acad. Sci. USA 98, 5164–5169 (2001).
Zamai, L. et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188, 2375–2380 (1998).
Williams, N. S. et al. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J. Immunol. 163, 2648–2656 (1999).
Roth, C., Carlyle, J. R., Takizawa, H. & Raulet, D. H. Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 13, 143–153 (2000).
Miller, J. S. & McCullar, V. Human natural killer cells with polyclonal lectin and immunoglobulin-like receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 98, 705–713 (2001).
Kim, S. et al. In vivo developmental stages in murine natural killer cell maturation. Nature Immunol. 3, 523–528 (2002).
Iizuka, K. et al. Requirement for membrane lymphotoxin in natural killer cell development. Proc. Natl Acad. Sci. USA 96, 6336–6340 (1999).
Wu, Q. et al. Signal via lymphotoxin-β R on bone marrow stromal cells is required for an early checkpoint of NK cell development. J. Immunol. 166, 1684–1689 (2001).
Ogasawara, K. et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391, 700–703 (1998).
Ohteki, T. et al. The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-αβ+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells. J. Exp. Med. 187, 967–972 (1998).
Briard, D., Brouty-Boye, D., Azzarone, B. & Jasmin, C. Fibroblasts from human spleen regulate NK cell differentiation from blood CD34+ progenitors via cell surface IL-15. J. Immunol. 168, 4326–4332 (2002).
Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL-7R expression in T−B+NK+ severe combined immunodeficiency. Nature Genet. 20, 394–397 (1998).
DiSanto, J. P. et al. Absence of interleukin 2 production in a severe combined immunodeficiency disease syndrome with T cells. J. Exp. Med. 171, 1697–1704 (1991).
Kundig, T. M. et al. Immune responses in interleukin-2-deficient mice. Science 262, 1059–1061 (1993).
Sharfe, N., Dadi, H. K., Shahar, M. & Roifman, C. M. Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc. Natl Acad. Sci. USA 94, 3168–3171 (1997).
Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771–780 (2000).
Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669–676 (1998). References 71 and 72 illustrate the essential and non-redundant role of IL-15 and its receptor in mouse NK-cell development. A defect in the human IL-15 receptor results in NK-cell deficiency, as described in reference 46.
Suzuki, H., Duncan, G. S., Takimoto, H. & Mak, T. W. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor β chain. J. Exp. Med. 185, 499–505 (1997).
Di Santo, J. P., Müller, W., Guy-Grand, D., Fischer, A. & Rajewsky, K. Lymphoid development in mice with a targeted deletion of the interleukin-2 receptor γ chain. Proc. Natl Acad. Sci. USA 92, 377–381 (1995).
Noguchi, M. et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147–157 (1993).
Gilmour, K. C. et al. Defective expression of the interleukin-2/interleukin-15 receptor β subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 98, 877–879 (2001).
Lodolce, J. P., Burkett, P. R., Boone, D. L., Chien, M. & Ma, A. T cell-independent interleukin 15Rα signals are required for bystander proliferation. J. Exp. Med. 194, 1187–1194 (2001).
Pereno, R. et al. IL-15/IL-15Rα intracellular trafficking in human cells and protection from apoptosis. Ann. NY Acad. Sci. 876, 236–245 (1999).
Dubois, S., Mariner, J., Waldmann, T. A. & Tagaya, Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17, 537–547 (2002). This paper proposes a new model for the function of IL-15.
Giri, J. G. et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J. 14, 3654–3663 (1995).
Cerwenka, A. & Lanier, L. L. Ligands for natural killer cell receptors: redundancy or specificity. Immunol. Rev. 181, 158–169 (2001).
Raulet, D. H., Vance, R. E. & McMahon, C. W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291–330 (2001).
Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795–799 (1998).
Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E. & Raulet, D. H. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188, 1841–1848 (1998).
Smith, H. R. et al. Nonstochastic coexpression of activation receptors on murine natural killer cells. J. Exp. Med. 191, 1341–1354 (2000).
Ljunggren, H. G. & Karre, K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11, 237–244 (1990).
Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R. & Phillips, J. H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136, 4480–4486 (1986).
Smyth, M. J., Hayakawa, Y., Takeda, K. & Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Rev. Cancer 2, 850–861 (2002). An excellent review on recent advances in our understanding of the role of NK cells in cancer and the possibility of using them in therapy.
Parrish-Novak, J. et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57–63 (2000).
Kasaian, M. T. et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16, 559–569 (2002).
Orange, J. S. et al. Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. J. Clin. Invest. 109, 1501–1509 (2002).
Zhou, J., Zhang, J., Lichtenheld, M. G. & Meadows, G. G. A role for NF-κB activation in perforin expression of NK cells upon IL-2 receptor signaling. J. Immunol. 169, 1319–1325 (2002).
Kaisho, T. et al. Impairment of natural killer cytotoxic activity and interferon-γ production in CCAAT/enhancer binding protein γ-deficient mice. J. Exp. Med. 190, 1573–1582 (1999).
Lohoff, M. et al. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J. Exp. Med. 192, 325–336 (2000).
Ito, A. et al. Inhibitory effect on natural killer activity of microphthalmia transcription factor encoded by the mutant mi allele of mice. Blood 97, 2075–2083 (2001).
Lacorazza, H. D. et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 17, 437–449 (2002).
Cooper, M. A. et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97, 3146–3151 (2001). This paper provides the first clear evidence that human NK cells can be divided in two distinct subsets on the basis of expression of cell-surface markers and division of labour. Whether this applies to mouse NK cells is not known.
Benlagha, K., Kyin, T., Beavis, A., Teyton, L. & Bendelac, A. A thymic precursor into the NK T cell lineage. Science 296, 553–555 (2002).
Loza, M. J. & Perussia, B. Final steps of natural killer cell maturation: a model for type 1–type 2 differentiation? Nature Immunol. 2, 917–924 (2001).
Loza, M. J., Peters, S. P., Zangrilli, J. G. & Perussia, B. Distinction between IL-13 and IFN-γ natural killer cells and regulation of their pool size by IL-4. Eur. J. Immunol. 32, 413–423 (2002).
Peritt, D. et al. Differentiation of human NK cells into NK1 and NK2 subsets. J. Immunol. 161, 5821–5824 (1998).
Hoshino, T., Wiltrout, R. H. & Young, H. A. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 162, 5070–5077 (1999).
Lauwerys, B. R., Garot, N., Renauld, J. C. & Houssiau, F. A. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J. Immunol. 165, 1847–1853 (2000).
Ranson, T. et al. IL-15 is an essential mediator of peripheral NK cell homeostasis. Blood (in the press)
Cooper, M. A. et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100, 3633–3638 (2002).
Frey, M. et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J. Immunol. 161, 400–408 (1998).
Fehniger, T. A. et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell derived IL-2: a potential new link between adaptive and innate immunity. Blood 101, 3052–3057 (2003).
Moffet-King, A. Natural killer cells and pregnancy. Nature Rev. Immunol. 2, 656–663 (2002).
Croy, B. A., Chantakru, S., Esadeg, S., Ashkar, A. A. & Wei, Q. Decidual natural killer cells: key regulators of placental development. J. Reprod. Immunol. 57, 151–168 (2002).
Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. The biology of human natural killer-cell subsets. Trends Immunol. 22, 633–640 (2001).
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A. & Caligiuri, M. A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100, 1935–1947 (2002).
Caligiuri, M. A. et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91, 123–132 (1993).
Fehniger, T. A. et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J. Clin. Invest. 106, 117–124 (2000).
Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443–446 (2000).
Meropol, N. J. et al. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. 46, 318–326 (1998).
Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097–2100 (2002). In a mismatched transplantation setting, NK cells prevented relapse of acute myeloid leukaemia. Importantly, these alloreactive NK cells did not cause graft-versus-host disease, mediated graft-versus-leukaemia effects and allowed better engraftment of donor cells.
Minagawa, M. et al. Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor β-chain-deficient mice. J. Immunol. 169, 4153–4160 (2002).
Piguet, P. F., Grau, G., Irle, C. & Vassalli, P. Administration of recombinant interleukin 2 to mice enhances production of hemopoietic and natural killer cells. Eur. J. Immunol. 16, 1257–1261 (1986).
Nakajima, H. et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J. Immunol. 168, 643–650 (2002).
Gilliland, D. G. Molecular genetics of human leukemias: new insights into therapy. Semin. Haematol. 39, 6–11 (2002).
Forbes, L. V. et al. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene 21, 5981–5989 (2002).
Hongyo, T. et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 60, 2345–2347 (2000).
Fehniger, T. A. et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193, 219–231 (2001).
Marks-Konczalik, J. et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl Acad. Sci. USA 97, 11445–11450 (2000).
Acknowledgements
F.C. and J.P.D. are supported by grants from the Pasteur Institute, Inserm, Association pour la Recherche sur le Cancer, Ligue National Contre le Cancer, and the Fondation pour la Recherche Medicale. M.A.C. is supported in part by grant from the United States National Cancer Institute. We thank C. A. Vosshenrich, B. Becknell and T. Ranson for critical reading of the review.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
LocusLink
FURTHER INFORMATION
Glossary
- HAEMATOPOIETIC STEM CELLS
-
(HSCs). These are defined functionally as the one cell that is capable of self-renewing and generating all of the cell types present in the blood. Common myeloid progenitors, common lymphoid progenitors, early lymphoid progenitors and natural-killer-cell precursors are committed progenitors that are derived from HSCs.
- NK-CELL PRECURSORS
-
(NKPs). Cells that can differentiate into natural killer (NK) cells but no other haematopoietic lineage. The expression of the interleukin-2 receptor β-chain by early lymphoid precursors seems to indicate commitment to the NK-cell lineage.
- DI GEORGE SYNDROME
-
A clinical syndrome that is characterized by congenital aplasia or hypoplasia of the thymus and the parathyroid glands, associated with facial and cardiovascular malformations. In 85% of cases, it is caused by a de novo deletion of chromosome 22q11.2
- DEVELOPMENTAL INTERMEDIATES
-
Phenotypically defined cell types that are known to be part of a developmental pathway, and that, on the basis of expression of cell-surface markers or gene-expression profiles, can be placed precisely in that pathway.
- COMMITMENT OF HAEMATOPOIETIC STEM CELLS
-
Lineage commitment is a progressive process that results in loss of the ability to differentiate into multiple lineages. This process is associated with a change in the gene-expression profiles and often correlates with the acquisition of expression of specific cell-surface markers, which are useful for the identification of particular stages of development.
- NK-CELL REPERTOIRE
-
The collection of cell-surface receptors expressed by a population of NK cells. Individual NK cells can express combinations of activating and inhibitory NK-cell receptors; the sum total of different NK-cell clones in the organism defines the 'repertoire'. NK-cell receptors are expressed in a sequential, but stochastic manner during maturation in the bone marrow.
- SELF-TOLERANCE
-
With reference to NK-cell differentiation, the capacity of NK cells to recognize self-MHC molecules (typically classical and non-classical MHC class I gene products) through inhibitory receptors with the resultant downregulation of NK-cell effector functions.
- EFFECTOR FUNCTIONS
-
NK cells were discovered for their ability to spontaneously kill tumour cell lines in vitro. Besides natural cytotoxicity, NK cells can mediate other forms of killing, such as antibody-dependent cellular cytotoxicity. NK cells are also potent producers of interferon-γ, tumour-necrosis factor and granulocyte–macrophage colony-stimulating factor, which prime the adaptive immune system, stimulate myeloid growth and mediate anti-virus and cytotoxic effects. NK cells can also produce chemokines, which attract other cells of the immune system.
- CMPS, CLPS AND ELPS
-
A group of haematopoietic precursors that are committed to either the myeloid (common myeloid progenitor), or the lymphoid (common lymphoid progenitor or early lymphoid progenitor) lineage. CMPs give rise to monocytes, granulocytes, erytrocytes, megakaryocytes and mast cells, whereas CLPs/ELPs give rise to B, T and NK cells.
- HOMEOSTASIS
-
A self-regulating process by which biological systems maintain stability, while adjusting to conditions that are optimal for survival. When applied to lymphocyte subsets, this refers to the mechanisms that regulate cell numbers in the peripheral pool.
- MISSING-SELF HYPOTHESIS
-
Almost 20 years ago, Klas Kärre predicted the existence of inhibitory receptors expressed by NK cells that recognize self-MHC class I molecules87. The lack of expression of the relevant MHC by target cells (missing self) consequently activates NK cells and results in target-cell elimination.
- ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
-
(ADCC). Cells that are coated with antibodies are targeted and destroyed by NK cells, macrophages and granulocytes. On NK cells, ADCC is mediated by the Fc receptor complex (CD16).
- NKT CELLS
-
T cells that express antigen receptors of limited variability and that share markers and functions with NK cells. NKT cells are potent producers of cytokines and are heterogeneous in terms of target recognition, anatomical localization and functions.
Rights and permissions
About this article
Cite this article
Colucci, F., Caligiuri, M. & Di Santo, J. What does it take to make a natural killer?. Nat Rev Immunol 3, 413–425 (2003). https://doi.org/10.1038/nri1088
Issue Date:
DOI: https://doi.org/10.1038/nri1088
This article is cited by
-
Interferon-epsilon is a novel regulator of NK cell responses in the uterus
EMBO Molecular Medicine (2024)
-
Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response
Nature Communications (2021)
-
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
Journal for ImmunoTherapy of Cancer (2019)
-
CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse
Scientific Reports (2019)